Reuters -- AstraZeneca’s (AZN.L) new heart medicine Brilinta won a green light from regulators on Europe on Friday, boosting prospects for its biggest drug hope which analysts expect to become a multi-billion-dollar a year seller.
Reuters -- AstraZeneca’s (AZN.L) new heart medicine Brilinta won a green light from regulators on Europe on Friday, boosting prospects for its biggest drug hope which analysts expect to become a multi-billion-dollar a year seller.